Results 271 to 280 of about 226,603 (334)
Socioeconomic and psychosocial determinants of substance misuse - a national perspective. [PDF]
Forensic Sci Med PatholStephenson L +2 more
europepmc +1 more source
Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks
British Journal of Clinical Pharmacology, EarlyView.The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou +2 more
wiley +1 more source
Substance misuse disorder in Saudi Arabia: A comprehensive examination of current demographic patterns, trends, and intervention requirements. [PDF]
Saudi Pharm JTobaiqy M, Al-Asmari AI.
europepmc +1 more source
Zuranolone: A case study in (regulatory) rush to judgement?
British Journal of Clinical Pharmacology, EarlyView.Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove +4 more
wiley +1 more source
A group version of the OurRelationship program within residential substance use treatment: preliminary evidence for improving responses to romantic relationship conflict for those dealing with substance misuse. [PDF]
Front PsycholKarantzas GC +9 more
europepmc +1 more source